Portfolio News

 

   
December 2012
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $4.4m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
December 2012
Convergence Pharmaceuticals investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Convergence Pharmaceuticals, focused on the development of novel analgesics with commercially attractive efficacy, responder-rate and side effect profiles as part of a $26.6m series A financing round.  ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
October 2012
Health Essentials
SV Life Sciences notes the SV Life Science Fund V invested in Health Essentials, a leading provider of post-acute care management services as part of a $34m financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
October 2012
Bicycle Therapeutics Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Bicycle Therapeutics, using its developing platform technology bicyclic peptide to select drug candidates as part of a £3.75m seed financing round. ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
October 2012
Good Start Genetics Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Good Start Genetics, a pre-pregnancy genetic testing business as part of an $14m Series B financing round. ...

Read more

Team - David Guyer
September 2012
Nordic Consulting Partners Investment
SV Life Sciences notes that SV Life Science Fund V invested in Nordic Consulting Partners, a leading Healthcare IT (HIT) consulting firm focused exclusively on the implementation of Epic systems at healthcare providers as part of a $22m financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
September 2012
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $5m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
August 2012
Neurotech Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases as part of a $10m bridge loan financing round.  ...

Read more

Team - David Guyer
July 2012
U.S. Renal Care Investment
SV Life Sciences notes that SV Life Science fund V invested in U.S. Renal Care, dialysis service to patients with end stage renal disease (ESRD) as part of a $20m series financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
June 2012
EBR Systems - Investment
SV Life Sciences Fund III invested in EBR Systems, developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure as part of a $8m bridge loan financing round.  ...

Read more

Team - James Garvey, David Milne
June 2012
Karus Therapeutics Limited Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Karus Therapeutics, an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer as part of a $35m (including conversion of $3m bridge) series B financing round.  ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
May 2012
US Renal Care - Exit
SV Life Sciences notes that US Renal Care completed a $137m Dividend Recapitalization, which required increasing Senior Debt from $131m to $215m and increasing Mezzanine Debt from $40.5m to $100m.  ...

Read more

Team - Eugene Hill
May 2012
Patient Care Exit
SV Life Sciences notes that in May 2010 – Almost Family (Nasdaq: AFAM) entered into a definitive agreement to acquire all stock of Patient Care. The total purchase price for the stock is $45.2m, subject to a working capital adjustment ...

Read more

Team - Eugene Hill
May 2012
Neurotech Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases as part of a $2m bridge loan financing round. ...

Read more

Team - David Guyer

⇧ Back to top